Results 161 to 170 of about 30,003 (287)
The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 895-908, July 2025.Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley +1 more source
Global Health Research and PolicyBackground The Chinese biosimilar industry has demonstrated rapid growth in recent years. Limited evidence is available about biosimilar uptake at the national level.
Qiyou Wu +4 more
doaj +1 more source
The Portuguese Society of Rheumatology position paper on the use of biosimilars [PDF]
, 2014 Biotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs intended to be as efficacious ...
Aguiar, R +41 more
core
Friction and Wear Characterizations in Electrospun Nanofibrous Scaffolds for Cartilage Engineering
Nano Select, Volume 6, Issue 7, July 2025.Articular cartilage (AC)‐engineered electrospun scaffolds have experienced a surge in interest in publication in recent years. However, nanofiber frictional properties are poorly explored in the existing literature. We evaluated the effect of countersurface, speed, and hydrophilicity on nanofibers.
André Mathias Souza Plath +2 more
wiley +1 more source
Biosimilars: Are They Ready for Primetime in the United States? [PDF]
, 2011 Bradford R. Hirsch, Gary H. Lyman
openalex +1 more source
Treatment Landscape in Pediatric Immune Thrombocytopenia: Addressing Unmet Needs
Pediatric Blood &Cancer, Volume 72, Issue 7, July 2025.ABSTRACT Pediatric immune thrombocytopenia (ITP) is associated with a multifaceted burden on children and their parents/caregivers due to bleeding, fatigue, activity restrictions, and psychological distress. Most children recover within 12 months, but up to 30% develop chronic ITP.
Joana Azevedo +4 more
wiley +1 more source
How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome
British Journal of Haematology, Volume 207, Issue 1, Page 15-26, July 2025.Summary Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis‐stimulating agents (ESAs) are the first‐line treatment for anaemia in lower risk (LR)‐MDS. The European Medicines Agency (EMA) approved epoetin alpha for LR‐MDS‐related anaemia in 2017, based on evidence ...
Valeria Santini, Angela Consagra
wiley +1 more source
Bring on the Biosimilars! [PDF]
Biology of Blood and Marrow Transplantation, 2015 openaire +3 more sources
Biosimilars: Is absence of proof of difference, proof of absence of difference? [PDF]
, 2011 Mario Dicato
openalex +1 more source
Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)
Clinical &Experimental Ophthalmology, Volume 53, Issue 5, Page 523-528, July 2025.ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang +8 more
wiley +1 more source